Efficacy and Safety of DLBS1425 in Subjects With Advanced/Metastatic Breast Cancer

Inclusion Criteria: * Subjects diagnosed with Stage IIIB or IV breast cancer who have failed with or refuse to receive standard chemotherapies * Subjects with the expression of ER/PR negative; or positive ER/PR expression but have failed with or refuse to receive hormonal therapy * Either + or - expression of HER-2/neu gene * ECOG status = 0-2 * At least have 1 evaluable and measurable metastatic lesion as defined by RECIST criteria * Adequate haematological, liver, and renal function * At least 3 weeks has elapsed since prior chemotherapy, radiotherapy, biological/hormonal therapy * At least 4 weeks has elapsed since surgical biopsy / major surgery Exclusion Criteria: * Allergic to the trial product * Any other disease state, including infections or uncontrolled illnesses that could interfere with trial participation or trial evaluation * Concurrent herbal (alternative) medicine or food supplements suspected to have effect on cancer disease